39.26  1.76 (4.69%)		07-30 16:00
Open: 37.81 High: 39.32 Volume: 2,527,135		Pre. Close: 37.5 Low: 37.64 Market Cap: 1,193(M)

Short term
Mid term
Targets	6-month :	48.43	1-year :	51.93
Resists	First :	41.46	Second :	44.46
Pivot price	39.32
Supports	First :	36.61	Second :	30.46
MAs	MA(5) :	38.03	MA(20) :	40.18
	MA(100) :	32.73	MA(250) :	30.36
MACD	MACD :	0	Signal :	0.5
%K %D	K(14,3) :	23.2	D(3) :	13.9
RSI	RSI(14): 52.4
52-week	High :	44.46	Low :	22.72

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ ARKG ] has closed above bottom band by 48.8%. Bollinger Bands are 9.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	39.35 - 39.63	39.63 - 39.85
Low:	37.13 - 37.42	37.42 - 37.64
Close:	38.87 - 39.33	39.33 - 39.69

The ARKG fund operates as an actively managed Exchange Traded Fund (ETF), aiming to achieve significant capital appreciation over an extended period. Its investment strategy involves committing a minimum of 80% of its total assets, under typical market conditions, to equity securities issued by both domestic and international companies. These companies are strategically chosen from various sectors based on their direct connection to the fund's core investment principle: the groundbreaking genomics revolution.

Tue, 28 Jul 2026
ARK Genomic Revolution ETF rebounds after 15% d... - Pluang

Tue, 28 Jul 2026
ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable (BATS:ARKG) - Seeking Alpha

Tue, 28 Jul 2026
ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable (BATS:ARKG) - Seeking Alpha

Tue, 21 Jul 2026
ARKG and GNOM ETFs offer different genomic bets with varied risk and returns in 2026. - Pluang

Tue, 21 Jul 2026
ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins? - Yahoo Finance

Tue, 21 Jul 2026
ETF Showdown: ARKG vs GNOM, Which Genomics Fund Wins? - 24/7 Wall St.

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Neutral
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: CBOE
Sector: Financial Services
Industry: Asset Management
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.